Novocure's Phase 3 TRIDENT Trial Misses Primary Survival Endpoint in Newly Diagnosed Glioblastoma
核心洞察
The Phase 3 TRIDENT trial evaluating earlier initiation of Tumor Treating Fields (搜索) therapy in newly diagnosed glioblastoma (搜索) failed to meet its primary overall survival endpoint (HR 0.953; p=0.519).
Median overall survival was 17.7 months in the Early Start Arm versus 17.5 months in the Maintenance Start Arm, with no statistically significant difference between groups.
The trial confirmed the feasibility and safety of initiating TTFields therapy during chemoradiation, with no new safety signals observed and device-related adverse events consistent with prior studies.
Novocure (搜索) (NASDAQ: NVCR) announced that its Phase 3 TRIDENT trial failed to demonstrate a statistically significant improvement in overall survival for patients with newly diagnosed glioblastoma (搜索) who initiated Tumor Treating Fields (搜索) (TTFields) therapy at the start of chemoradiation compared to those who began treatment during the maintenance phase. The company's shares dropped 10% following the disclosure, reflecting investor disappointment in the outcome of the largest glioblastoma trial focused on optimizing TTFields integration into standard chemoradiotherapy.
The TRIDENT trial enrolled 981 patients who were randomized shortly after surgery. In the intent-to-treat (ITT) population, patients in the Early Start Arm achieved a median overall survival of 17.7 months, compared with 17.5 months for patients in the Maintenance Start Arm, yielding a hazard ratio of 0.953 and a p-value of 0.519.
Trial Design and Patient Population
TRIDENT was designed as a Phase 3 global, pivotal, randomized, open-label, two-arm, multicenter trial evaluating the effectiveness and safety of TTFields therapy given concomitantly with chemoradiation — consisting of radiation therapy and temozolomide — for newly diagnosed glioblastoma (搜索) patients, compared to initiating TTFields therapy once chemoradiation was complete. In both arms, TTFields therapy and maintenance temozolomide were continued following chemoradiation.
The median patient age was 60 years. Baseline characteristics were balanced across both arms: 38% of patients had a Karnofsky Performance Status (KPS) score of 70 or 80, 39% had a methylated MGMT promoter — a biomarker often associated with improved treatment response — and 5% had IDH-mutant tumors. The extent of surgical resection was also balanced, with 51% of patients undergoing gross total resection, 37% partial resection, and 12% biopsy only. Approximately 25% of patients did not proceed to the maintenance phase across both arms.
Survival Outcomes
Long-term survival data showed only modest differences between the two study arms. In the Early Start Arm, one-year, two-year, and three-year survival rates were 70.9%, 33.9%, and 22.5%, respectively. For patients in the Maintenance Start Arm, survival rates were 72.0%, 31.6%, and 18.4%. Although the early treatment group demonstrated slightly higher survival rates at the longer-term milestones, the differences were insufficient to achieve statistical significance.
The primary endpoint of the study was overall survival. Secondary endpoints included progression-free survival, one-, two-, and three-year survival rates, overall radiologic response based on the 2010 Response Assessment in Neuro-Oncology (RANO) criteria, next progression-free survival, progression-free survival at 6 and 12 months, and the severity and frequency of adverse events.
Safety Profile Remains Consistent
Despite missing its primary goal, the study confirmed that earlier use of TTFields therapy was both feasible and well tolerated. Novocure (搜索) reported no new safety signals during the trial, with device-related adverse events remaining consistent with previous clinical studies involving TTFields therapy in glioblastoma (搜索). The company stated that the safety profile observed in TRIDENT aligned with the established experience of using the treatment in glioblastoma patients.
Expert Commentary
"TRIDENT represents the largest glioblastoma (搜索) trial focused on optimizing the integration of Tumor Treating Fields (搜索) therapy into standard chemoradiotherapy," said Wenyin Shi, MD, PhD, Professor of Radiation Oncology and Co-Director of the Jefferson Brain Tumor Center at Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University. "Although the study did not meet its primary endpoint, it reaffirmed the clinical value of Tumor Treating Fields therapy and demonstrated promising signals that earlier initiation of TTFields treatment may improve outcomes for selected patients."
Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer at Novocure (搜索), added: "We are committed to improving the treatment of glioblastoma (搜索) and are grateful to our investigators and the patients and families who made the TRIDENT trial possible. The study did not meet its primary endpoint, but the results from TRIDENT demonstrated the feasibility and safety of initiating Tumor Treating Fields (搜索) therapy during chemoradiation. We look forward to sharing additional analyses from this trial, which may inform future treatment approaches for patients with specific characteristics."
Next Steps
Novocure (搜索) confirmed that the TRIDENT findings have been accepted for presentation at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentation is expected to provide clinicians and researchers with a more detailed review of the study's findings and their implications for future treatment strategies in glioblastoma (搜索). While the trial reinforced the safety and feasibility of early TTFields use, the failure to achieve the primary survival endpoint drove a sharp decline in the company's share price.